Immix Biopharma Investor Presentation Deck slide image

Immix Biopharma Investor Presentation Deck

N-GENIUS Platform: EXPAND Technology + COBRA Binder (2/2) CD3Zy 4-1BB Overview Of Custom EXPAND Technology + COBRA Binder in NXC-201 1 Proprietary Optimized CD37 - "CD3Zy" CD8 Transmembrane Protein 2 N-GENIUS PLATFORM Source:. Aherie, N., et al Haematologica. 2022; LaFleur, D. PEGS Boston. 2021 NXC-201 EXPAND Technology + COBRA Binder CD8 Hinge Tumor Binding Domain Proprietary Optimized CD8 Hinge Flexibility Delivers "Digital" Intracellular Signaling Eliminates Neurotoxicity, Reduce CRS Duration Enhances Efficacy In Heavily Pretreated Patients CD8 Signaling Protein "Single amino acid substitutions at key sites can affect CAR-T function over 200-fold range" 3 ●●● IMMİX S BIOPHARMA EXPAND Technology + COBRA Binder Modifications Proprietary Optimized COBRA Binder Enhances Tumor Binding + Ensures High Expression 9
View entire presentation